Financial reports
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
17 Mar 22
10-Q
2021 Q3
Quarterly report
9 Nov 21
Current reports
8-K
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K/A
Results of Operations and Financial Condition
8 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
8 Jan 24
8-K
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
8-K
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
25 May 23
8-K
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
11 May 23
8-K
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
9 Mar 23
8-K
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB
13 Feb 23
Registration and prospectus
S-8
Registration of securities for employees
14 Mar 24
S-3/A
Shelf registration (amended)
11 May 23
S-8
Registration of securities for employees
9 Mar 23
S-8
Registration of securities for employees
9 Mar 23
S-3
Shelf registration
9 Mar 23
S-8
Registration of securities for employees
10 Mar 22
424B4
Prospectus supplement with pricing info
11 Jan 21
S-1MEF
Registration of additional securities for an S-1
7 Jan 21
S-8
Registration of securities for employees
7 Jan 21
S-1/A
IPO registration (amended)
6 Jan 21
Other
EFFECT
Notice of effectiveness
19 May 23
CORRESP
Correspondence with SEC
16 May 23
CORRESP
Correspondence with SEC
17 Mar 23
CORRESP
Correspondence with SEC
9 Mar 23
UPLOAD
Letter from SEC
9 Mar 23
EFFECT
Notice of effectiveness
8 Jan 21
CERT
Certification of approval for exchange listing
7 Jan 21
SEC STAFF
SEC staff action: Order
7 Jan 21
CORRESP
Correspondence with SEC
6 Jan 21
UPLOAD
Letter from SEC
5 Jan 21
Ownership
4
Corrine Savill
23 Feb 24
4
NADIM AHMED
23 Feb 24
4
Jeffrey Trigilio
23 Feb 24
4
Jeffrey Alan Jones
23 Feb 24
4
Jennifer Michaelson
23 Feb 24
4
JACQUELYN L SUMER
23 Feb 24
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
Jovan-Embiricos Morana
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24